These insights serve to complement genomic studies, revealing the functional consequences of resistance and providing a foundation for the development of personalised therapies that aim to overcome or prevent resistance in HER2-positive breast cancer [31,32]. This evidence concerns the gene ERBB2 and breast carcinoma.